期刊
CURRENT DRUG TARGETS
卷 21, 期 5, 页码 477-498出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450120666191021110208
关键词
ROS; programmed cell death; bone marrow protection; chemotherapy; tumor; hematopoiesis
资金
- Public Welfare Technology Application Research Project of Zhejiang Province, Zhejiang, China [2015C37122]
- Zhejiang Provincial Natural Science Foundation of China, Zhejiang, China [LY17H160003]
Reactive oxygen species (ROS), an important molecule inducing oxidative stress in organisms, play a key role in tumorigenesis, tumor progression and recurrence. Recent findings on ROS have shown that ROS can be used to treat cancer as they accelerate the death of tumor cells. At present, pro-oxidant drugs that are intended to increase ROS levels of the tumor cells have been widely used in the clinic. However, ROS are a double-edged sword in the treatment of tumors. High levels of ROS induce not only the death of tumor cells but also oxidative damage to normal cells, especially bone marrow hemopoietic cells, which leads to bone marrow suppression and (or) other side effects, weak efficacy of tumor treatment and even threatening patients' life. How to enhance the killing effect of ROS on tumor cells while avoiding oxidative damage to the normal cells has become an urgent issue. This study is a review of the latest progress in the role of ROS-mediated programmed death in tumor treatment and prevention and treatment of oxidative damage in bone marrow induced by ROS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据